← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
EFTY
ETOILES CAPITAL GROUP CO., LTD
Valuation N/A
Industrials Risk 50 · Elevated
Price$15.02
Model IV—
P/IV—
Market implies +22.0%/yr vs model +50.0% · below model
EFXT
Enerflex Ltd.
Valuation N/A
Industrials Risk 27 · Moderate
Price$22.92
Model IV—
P/IV—
Limited data — see page
EGAN
EGAIN Corp
Valuation N/A
Technology Risk 32 · Moderate
Price$5.20
Model IV—
P/IV—
Market implies +29.3%/yr vs model +9.0% · above model
EGG
ENIGMATIG LTD
Valuation N/A
Industrials Risk 37 · Moderate
Price$2.86
Model IV—
P/IV—
Market implies +51.4%/yr vs model +2.0% · above model
EGHA
EGH Acquisition Corp.
Valuation N/A
Financial Services
Price$10.39
Model IV—
P/IV—
Limited data — see page
EGHAR
EGH Acquisition Corp.
Valuation N/A
Financial Services
Price$0.32
Model IV—
P/IV—
Limited data — see page
EGO
ELDORADO GOLD CORP /FI
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$43.75
Model IV—
P/IV—
Limited data — see page
EH
EHang Holdings Ltd
Valuation N/A
Industrials Risk 46 · Elevated
Price$4.53
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
EHI
WESTERN ASSET GLOBAL HIGH INCOME FUND INC.
Valuation N/A
Unknown
Price$5.61
Model IV—
P/IV—
Limited data — see page
EIC
Eagle Point Income Co Inc.
Valuation N/A
Unknown
Price$9.89
Model IV—
P/IV—
Limited data — see page
EICA
Eagle Point Income Co Inc.
Valuation N/A
Unknown
Price$24.92
Model IV—
P/IV—
Limited data — see page
EIIA
Eagle Point Institutional Income Fund
Valuation N/A
Unknown
Price$25.10
Model IV—
P/IV—
Limited data — see page
EIKN
Eikon Therapeutics, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$8.94
Model IV—
P/IV—
Limited data — see page
EIM
Eaton Vance Municipal Bond Fund
Valuation N/A
Unknown
Price$9.33
Model IV—
P/IV—
Limited data — see page
EL
ESTEE LAUDER COMPANIES INC
Valuation N/A
Consumer Defensive Risk 51 · Elevated
Price$98.22
Model IV—
P/IV—
Market implies +34.3%/yr vs model +2.6% · above model
ELBM
Electra Battery Materials Corp
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$0.52
Model IV—
P/IV—
Limited data — see page
ELC
ENTERGY LOUISIANA, LLC
Valuation N/A
Utilities
Price$19.31
Model IV—
P/IV—
Limited data — see page
ELDN
Eledon Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$2.78
Model IV—
P/IV—
Limited data — see page
ELE
Elemental Royalty Corp
Valuation N/A
Basic Materials
Price$21.43
Model IV—
P/IV—
Limited data — see page
ELMT
Elmet Group Co.
Valuation N/A
Industrials Risk 57 · Elevated
Price$16.19
Model IV—
P/IV—
Limited data — see page
ELOG
Eastern International Ltd.
Valuation N/A
Industrials Risk 42 · Elevated
Price$0.60
Model IV—
P/IV—
Limited data — see page
ELPW
Elong Power Holding Ltd.
Valuation N/A
Technology Risk 29 · Moderate
Price$2.74
Model IV—
P/IV—
Market implies +45.1%/yr vs model +2.0% · above model
ELTX
Elicio Therapeutics, Inc.
Valuation N/A
Healthcare Risk 47 · Elevated
Price$1.99
Model IV—
P/IV—
Market implies +34.0%/yr vs model +15.0% · above model
ELVA
Electrovaya Inc.
Valuation N/A
Technology Risk 29 · Moderate
Price$6.43
Model IV—
P/IV—
Limited data — see page
ELVN
Enliven Therapeutics, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$54.32
Model IV—
P/IV—
Limited data — see page
EMAT
Evolution Metals & Technologies Corp.
Valuation N/A
Technology Risk 42 · Elevated
Price$3.08
Model IV—
P/IV—
Limited data — see page
EMBJ
EMBRAER S.A.
Valuation N/A
Industrials Risk 59 · Elevated
Price$75.49
Model IV—
P/IV—
Limited data — see page
EMD
WESTERN ASSET EMERGING MARKETS DEBT FUND INC.
Valuation N/A
Unknown
Price$10.17
Model IV—
P/IV—
Limited data — see page
EMF
TEMPLETON EMERGING MARKETS FUND
Valuation N/A
Unknown
Price$22.60
Model IV—
P/IV—
Limited data — see page
EMIS
Emmis Acquisition Corp.
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
EMISR
Emmis Acquisition Corp.
Valuation N/A
Financial Services
Price$0.08
Model IV—
P/IV—
Limited data — see page
EMO
ClearBridge Energy Midstream Opportunity Fund Inc.
Valuation N/A
Unknown
Price$55.03
Model IV—
P/IV—
Limited data — see page
EMP
ENTERGY MISSISSIPPI, LLC
Valuation N/A
Utilities
Price$19.86
Model IV—
P/IV—
Limited data — see page
EMPD
Empery Digital Inc.
Valuation N/A
Consumer Cyclical Risk 27 · Moderate
Price$2.97
Model IV—
P/IV—
Market implies +60.7%/yr vs model +8.0% · above model
EMPG
Empro Group Inc.
Valuation N/A
Consumer Defensive
Price$17.36
Model IV—
P/IV—
Limited data — see page
ENGN
enGene Therapeutics Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.80
Model IV—
P/IV—
Limited data — see page
ENHA
Enhanced Group Inc.
Valuation N/A
Communication Services Risk 30 · Moderate
Price$1.56
Model IV—
P/IV—
Limited data — see page
ENJ
ENTERGY NEW ORLEANS, LLC
Valuation N/A
Utilities
Price$19.23
Model IV—
P/IV—
Limited data — see page
ENLV
Enlivex Ltd.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
ENO
ENTERGY NEW ORLEANS, LLC
Valuation N/A
Utilities
Price$20.61
Model IV—
P/IV—
Limited data — see page
ENPH
Enphase Energy, Inc.
Valuation N/A
Technology Risk 44 · Elevated
Price$36.66
Model IV—
P/IV—
Market implies +28.5%/yr vs model +2.0% · above model
ENTA
ENANTA PHARMACEUTICALS INC
Valuation N/A
Healthcare Risk 41 · Elevated
Price$12.96
Model IV—
P/IV—
Limited data — see page
ENTG
ENTEGRIS INC
Valuation N/A
Consumer Cyclical Risk 44 · Elevated
Price$140.37
Model IV—
P/IV—
Market implies +35.6%/yr vs model +8.4% · above model
ENTX
Entera Bio Ltd.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$2.84
Model IV—
P/IV—
Market implies +131.4%/yr vs model +2.0% · above model
ENVB
Enveric Biosciences, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.42
Model IV—
P/IV—
Limited data — see page
ENVX
Enovix Corp
Valuation N/A
Technology Risk 37 · Moderate
Price$3.10
Model IV—
P/IV—
Market implies +58.1%/yr vs model +15.0% · above model
EOD
ALLSPRING GLOBAL DIVIDEND OPPORTUNITY FUND
Valuation N/A
Unknown
Price$6.43
Model IV—
P/IV—
Limited data — see page
EOI
Eaton Vance Enhanced Equity Income Fund
Valuation N/A
Unknown
Price$19.69
Model IV—
P/IV—
Limited data — see page
EOS
Eaton Vance Enhanced Equity Income Fund II
Valuation N/A
Unknown
Price$21.29
Model IV—
P/IV—
Limited data — see page
EOT
Eaton Vance National Municipal Opportunities Trust
Valuation N/A
Unknown
Price$16.23
Model IV—
P/IV—
Limited data — see page
EPRX
EUPRAXIA PHARMACEUTICALS INC.
Valuation N/A
Healthcare Risk 38 · Moderate
Price$8.07
Model IV—
P/IV—
Limited data — see page
EPSM
Epsium Enterprise Ltd
Valuation N/A
Consumer Defensive Risk 44 · Elevated
Price$1.34
Model IV—
P/IV—
Market implies +16.4%/yr vs model +2.0% · above model
EQ
Equillium, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.11
Model IV—
P/IV—
Market implies +2.1%/yr vs model +15.0% · below model
EQNR
EQUINOR ASA
Valuation N/A
Energy Risk 38 · Moderate
Price$45.75
Model IV—
P/IV—
Limited data — see page
EQS
EQUUS TOTAL RETURN, INC.
Valuation N/A
Unknown Risk 33 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
EQX
Equinox Gold Corp.
Valuation N/A
Basic Materials Risk 32 · Moderate
Price$12.40
Model IV—
P/IV—
Limited data — see page
ERAS
Erasca, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$16.16
Model IV—
P/IV—
Limited data — see page
ERC
ALLSPRING MULTI-SECTOR INCOME FUND
Valuation N/A
Unknown
Price$9.02
Model IV—
P/IV—
Limited data — see page
ERH
ALLSPRING UTILITIES & HIGH INCOME FUND
Valuation N/A
Unknown
Price$11.22
Model IV—
P/IV—
Limited data — see page
ERIC
ERICSSON LM TELEPHONE CO
Valuation N/A
Technology
Price$10.31
Model IV—
P/IV—
Limited data — see page